Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen.
Galimberti S, Nagy B, Benedetti E, Pacini S, Brizzi S, Caracciolo F, Papineschi F, Ciabatti E, Guerrini F, Fazzi R, Canestraro M, Petrini M. Galimberti S, et al. Among authors: ciabatti e. Leuk Lymphoma. 2007 Aug;48(8):1502-9. doi: 10.1080/10428190701402895. Leuk Lymphoma. 2007. PMID: 17701580 Clinical Trial.
The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms.
Galimberti S, Palumbo GA, Caracciolo F, Benedetti E, Pelosini M, Brizzi S, Ciabatti E, Fazzi R, Stelitano C, Quintana G, Conte E, Tibullo D, Di Raimondo F, Petrini M. Galimberti S, et al. Among authors: ciabatti e. J Chemother. 2007 Jun;19(3):315-21. doi: 10.1179/joc.2007.19.3.315. J Chemother. 2007. PMID: 17594928 Clinical Trial.
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldero G, Gaidano G, Musto P, Petrini M, Federico M. Galimberti S, et al. Among authors: ciabatti e. Clin Cancer Res. 2014 Dec 15;20(24):6398-405. doi: 10.1158/1078-0432.CCR-14-0407. Epub 2014 Oct 14. Clin Cancer Res. 2014. PMID: 25316810 Free article.
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.
Salehzadeh S, Guerrini F, Pizzano U, Grassi S, Ciabatti E, Iovino L, Buda G, Caracciolo F, Benedetti E, Orciuolo E, Pelosini M, Consani G, Carulli G, Metelli MR, Martini F, Mazziotta F, Mazzantini E, Rossi P, Tavarozzi R, Ricci F, Petrini M, Galimberti S. Salehzadeh S, et al. Among authors: ciabatti e. Cancer Cell Int. 2019 Apr 4;19:83. doi: 10.1186/s12935-019-0807-0. eCollection 2019. Cancer Cell Int. 2019. PMID: 30992690 Free PMC article.
Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line.
Galimberti S, Canestraro M, Maffei R, Marasca R, Guerrini F, Piaggi S, Ciabatti E, Petrini M. Galimberti S, et al. Among authors: ciabatti e. Leukemia. 2009 Oct;23(10):1935-8. doi: 10.1038/leu.2009.119. Epub 2009 Jul 23. Leukemia. 2009. PMID: 19626048 No abstract available.
The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study.
Galimberti S, Ciabatti E, Ercolano G, Grassi S, Guerrini F, Cecconi N, Rousseau M, Cervetti G, Mazziotta F, Iovino L, Falzetti F, Falcinelli F, Bosi A, Rigacci L, Kovalchuk S, Vallisa D, Macchia L, Ciancia E, Petrini M. Galimberti S, et al. Among authors: ciabatti e. Front Pharmacol. 2017 Jun 29;8:413. doi: 10.3389/fphar.2017.00413. eCollection 2017. Front Pharmacol. 2017. PMID: 28706485 Free PMC article.
54 results